| Variable | HIV +ve women (24) | HIV −ve women (200) | Pearson chi-square test |
| Age range 21 - 30 31 - 40 41 - 50 51 - 60 61 - 70 >70 |
0 6 (25%) 10 (41.7%) 8 (33.3%) 0 0 |
16 (8%) 24 (12%) 40 (20%) 64 (32%) 46 (23%) 10 (5%) |
*0.007 |
| Age at 1st coitus <10 10 - 13 14 - 17 18 - 21 ≥22 Unindicated |
6 (25%) 14 (58.3%) 4 (16.7%) 0 0 0 |
16 (8%) 94 (47%) 60 (30%) 24 (12%) 4 (2%) 2 (1%) |
*0.037 |
| Clinical Diagnosis Cervical cancer Ovarian cancer Uterine Cancer Choriocarcinoma/GTD Vulva cancer |
18 (75%) 2 (8.3%) 0 0 4 (16.7%) |
94 (47%) 62 (31%) 24 (12%) 10 (5%) 10 (5%) | *0.003 |
| Histopathology of specimen Cervix No histology (Discharged AMA—No treatment) Adenocarcinoma Adeno-squamous Ca Well diff. invasive SCC Undifferentiated SCC Ovary Serous cyst-adenoCa Mucinous cystadenoCa Endometriod Ca Granulosa cell Tumour Dysgerminoma Mixed Mullerian Tumour Sertoli-Leydig cell Tumou Immature teratoma Serous Papillary Ca Uterus Endometriod adenocarcinoma Uterine rhabdomyosarcoma Chorio-Carcinoma/GTD Vulva Invasive Sq. cell Ca Verrucous carcinoma |
0 0 0 18 (75%) 0
2 (8.3%) 0 0 0 0 0 0 0 0
0 0 0
2 (8.3%) 2 (8.3%) |
10 (5%) 12 (6%) 4 (2%) 66 (33%) 2 (1%)
34 (17%) 8 (4%) 3 (1.5%) 8 (4%) 2 (1%) 2 (1%) 2 (1%) 2 (1%) 1(0.5%)
22 (11%) 2 (1%) 10 (5%)
10 (5%) 0 |
|
| FIGO Stage of Illness 1 2 3 4 |
0 2 (8.3%) 14 (58.3%) 8 (33.3%) |
26 (13%) 38 (19%) 54 (27%) 82 (41%) |
*0.008 |
| Status at study period (06/18-02/19) Alive Alive with recurrence Terminally ill Lost to follow-up Dead |
4 (16.7%) 0 0 18 (75%) 2 (8.3%) |
52 (26%) 10 (5%) 14 (7%) 76 (38%) 48 (24%) |
*0.011 |